Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
José Vicente GilAccredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain.ORCID 0000-0003-2097-4796
Sandra de Las HerasAccredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain.
Alberto MirallesAccredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain.
Claudia SargasAccredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain.ORCID 0000-0001-8144-7995
Marta LlopMolecular Biology Unit, Clinical Analysis Service, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.ORCID 0000-0002-0106-7296
Rebeca Rodríguez-VeigaHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.ORCID 0000-0003-2139-8540
Laura Torres-MiñanaHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.ORCID 0009-0005-6930-8059
Blanca BoludaHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.
Isabel Cano-FerriHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.
Evelyn Acuña-CruzHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.ORCID 0000-0003-2869-369X
Irene NavarroHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.
Pilar Lloret-MadridHematology Department, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain.
Pau MontesinosCentro de Investigación Biomédica en Red de Cáncer, CIBERONC Instituto de Salud Carlos III, 28029 Madrid, Spain.
Eva BarragánAccredited Research Group on Hematology, Instituto de Investigación Sanitaria la Fe, 46026 Valencia, Spain.
Funding
Scientific Foundation of the Spanish Association Against Cancer PRDVA246268GIL
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Feasible and Rapid Screening of · full record | OpenQuestion